Publications by authors named "S Hecker-Nolting"
Background: Osteosarcoma may arise as a secondary malignancy following rhabdomyosarcoma (RMS). We utilized the Cooperative Osteosarcoma Study Group (COSS) database to better understand this association.
Patients And Methods: The COSS database (1980-05/2023) was searched for patients whose osteosarcoma was preceded by RMS.
Purpose: Prognostic factors have been well described for osteosarcoma, but analyses evaluating the further course of long-term survivors are lacking. We used the large database of the Cooperative Osteosarcoma Study Group (COSS) to perform such an analysis.
Patients And Methods: The COSS database 1980-04/2019 was searched for 5-year survivors of primary high-grade central osteosarcoma of the extremities or trunk.
Article Synopsis
- Osteosarcoma and Ewing sarcoma are challenging bone tumors primarily affecting younger individuals, with low survival rates even after various treatment approaches.
- Current research on targeted therapies and immunotherapies has been ineffective, highlighting the need for a deeper understanding of the tumor biology and the immune microenvironment.
- A new Europe-wide framework for systematic sampling and analysis of patient samples has been proposed, supported by international consortia aiming to set guidelines that will enhance research collaboration and ultimately improve treatment outcomes.
Osteosarcoma Arising as a Secondary Malignancy following Treatment for Hematologic Cancer: A Report of 33 Affected Patients from the Cooperative Osteosarcoma Study Group (COSS).
Cancers (Basel)
May 2024
Purpose: Osteosarcoma may arise as a secondary cancer following leukemias or lymphomas. We intended to increase the knowledge about such rare events.
Patients And Methods: We searched the Cooperative Osteosarcoma Study Group's database for individuals who developed their osteosarcoma following a previous hematological malignancy.
Article Synopsis
- The study focused on 83 patients with high-grade osteosarcoma who had multi-systemic metastases at diagnosis to assess characteristics, treatments, and survival outcomes.
- Among these, only 10.8% achieved complete surgical remission, with overall survival rates dropping significantly at 1, 2, and 5 years post-diagnosis.
- Key negative prognostic factors included elevated alkaline phosphatase and multiple bone metastases, while better outcomes were linked to complete surgical resection and effective chemotherapy.